CRISPR Therapeutics AG (CRSP) shares rallied 6.9% in the last trading session to close at $84.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.9% gain over the past four weeks. Earlier this week, the company announced that the European Commission has granted conditional marketing authorization to Casgevy for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in p ...